Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

Published in:

British Journal of Cancer, 2024, v. 130, n. 8, p. 1269, doi. 10.1038/s41416-024-02604-y

By:

• Karapetis, C. S.;
• Liu, H.;
• Sorich, M. J.;
• Pederson, L. D.;
• Van Cutsem, E.;
• Maughan, T.;
• Douillard, J. Y.;
• O'Callaghan, C. J.;
• Jonker, D.;
• Bokemeyer, C.;
• Sobrero, A.;
• Cremolini, C.;
• Chibaudel, B.;
• Zalcberg, J.;
• Adams, R.;
• Buyse, M.;
• Peeters, M.;
• Yoshino, T.;
• de Gramont, A.;
• Shi, Q.

Publication type:

Article